1-3 of 3
Anupama Kalsekar
Close
Sort by
Journal Articles

Effectiveness of Chemo-Immunotherapy (CIT) and Novel Therapies in Second or Later Line of Therapy (2L+) for Patients with Relapsed/Refractory (R/R) Aggressive Large B-Cell Lymphoma (LBCL)

Loretta J. Nastoupil, Clark R. Andersen, Amy Ayers, Yucai Wang, Thomas M. Habermann, Dai Chihara, Brad S. Kahl, Brian K. Link, Jonathon B. Cohen, Peter Martin, Izidore S. Lossos, Carla Casulo, Ruitao Lin, Ziyi Li, Melissa C. Larson, Matthew J. Maurer, Lynn Huynh, Chi Gao, Ramya Ramasubramanian, Mei Sheng Duh, Alex Mutebi, Tongsheng Wang, Monika Jun, Anthony Wang, Rajesh Kamalakar, Anupama Kalsekar, James R. Cerhan, Christopher R. Flowers
Journal: Blood
Blood (2023) 142 (Supplement 1): 309.
https://doi.org/10.1182/blood-2023-174497
Published: 2023
Journal Articles

Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)

Tycel Phillips, Pieternella Lugtenburg, Anupama Kalsekar, Alex Mutebi, Anthony Wang, Julie Blaedel, Katherine Kosa, Susan Martin, Mariana Sacchi, Catherine Thieblemont
Journal: Blood
Blood (2022) 140 (Supplement 1): 8022–8023.
https://doi.org/10.1182/blood-2022-159544
Published: 2022
Journal Articles

Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika P. Jun, Anupama Kalsekar, Fernando Rivas Navarro, Anthony Wang, Rajesh Kamalakar, Mariana Sacchi, Brian Elliott
Journal: Blood
Blood (2022) 140 (Supplement 1): 6693–6694.
https://doi.org/10.1182/blood-2022-159569
Published: 2022